PerkinElmerCEO说公司不会出售

PerkinElmer公司CEO：Rob Friel

　　“我们没有打算出售公司，这不是什么我们在董事会层面讲的事情。” 罗伯特弗里尔Robert Friel在路透社的独家电话采访中告诉记者。

　　弗里尔正对上周四彭博社的报告作出回应，彭博社报告说这家公司刚刚错过了购买更大的诊断公司贝克曼.库尔特（BEC.N），并正在和美国银行工作，因为它决定是否寻求另一收购或把自己挂牌出售。

　　“我们不是与美国银行工作，” 在宾夕法尼亚州参加一个家庭葬礼的弗里尔说，“关于我们现在将决定出售公司的想法不是基于事实的。”

　　上周四，PerkinElmer的股票跳涨7个百分点，其交易量超过平均交易量股的4倍。这促使弗里尔反击上述报告，即使这意味着股价会降低。

　　“我认为在该情况下这可能是正确的做法，因为我怀疑，助长了今天交易量蓄积的因素不是真的。”

　　在数小时的盘后交易后，PerkinElmer股票部分回落，从纽约证券交易所收盘时的 $27.72回落到$26.99。

　　弗里尔拒绝评论关于PerkinElmer投标贝克曼收购直到最后一刻的报告——这是一宗比它以前的典型收购高许多倍的交易，会涉及到重大的债务处理。熟知该次招标的人士告诉路透社，PerkinElmer一直试图购买Beckman。

　　丹纳赫公司（DHR.N）最终以58亿美元收购贝克曼，这几乎是PerkinElmer年收入的近3倍。

　　当被问及他是否会考虑另一宗该规模的交易时，弗里尔说，“在大多数情况下，我们看到更大交易的风险有时会高于其潜在的好处。”

　　“像这种规模的交易，必须是我们真正感到会为我们的股东们创造显著价值的，必须是极具有吸引力以至于我们感到我们真正需要好好看一看的。”他补充说。

　　PerkinElmer主要销售科学仪器、医疗检测设备和环境安全监控产品，在历史上每年都进行几次收购，规模在5000万美元到1亿美元之间。

　　弗里尔表示，公司正在关注较大的交易。

　　“我们倾向于先开始作一些比之前稍大一些规模的收购。我们获得了一个渠道的伙伴，看起来很有趣，我们将会收购更多这些在几百万美元范围的渠道。”他说。

　　“我们拥有大量的现金，因此我们有相当大的借贷能力，我们觉得自己有很好的财务状况，可以走出去做些1~2亿美元的收购，以扩充我们已有的能力。我觉得这就是你们将要从我们这里展望的未来。”弗里尔说。

　　他倾向于在诊断、试剂、服务和软件领域进行收购，且有助于扩大公司的地理覆盖范围。

　　“我们公司的核心战略在根本上是建立在更小规模的收购基础上的。”

　　（Reporting by Bill Berkrot； Editing by Richard Chang）

相关报道：

PerkinElmer回应将可能被出售的传闻

PerkinElmer 25美分错失收购贝克曼库尔特良机

参考英文原文：

Exclusive: PerkinElmer CEO says company not for sale

(Reuters) - PerkinElmer Inc's (PKI.N) chief executive said a report that the company was deciding whether to put itself up for sale was not based on fact and "completely not true."

"We are not putting the company up for sale. It's not anything we talked about at the board level," Robert Friel told Reuters in an exclusive telephone interview.

Friel was reacting to a Bloomberg report on Thursday that said the company had just missed out on buying much larger diagnostics company Beckman Coulter Inc (BEC.N) and was working with Bank of America as it decides whether to seek another acquisition or put itself up for sale.

"We are not working with Bank of America," said Friel, who was in Pennsylvania for a family funeral. "This thought that we would now decide to position the company for sale is not based in fact."

PerkinElmer's shares jumped 7 percent with more than four times the average volume of shares trading on Thursday, prompting Friel to knock down the report even if it meant sending the share price lower.

"I saw the (Bloomberg) article and when I saw the volume of our stock today I felt we really needed to address it," Friel said.

"In this case I think it's probably the right thing to do because what I suspect is what is fueling the volume of the stock today is just not true."

PerkinElmer shares did give back some of its gains in after-hours trading, falling to $26.99 from a New York Stock Exchange close at $27.72.

Friel declined to comment on the report that PerkinElmer was in the bidding for Beckman until the eleventh hour -- a deal that would have been many times larger that its typical acquisitions, and one that would have involved taking on significant debt. People familiar with the bidding told Reuters that PerkinElmer had been trying to buy Beckman.

Danaher Corp (DHR.N) eventually landed Beckman for $5.8 billion, nearly three times PerkinElmer's annual revenue.

Asked if he would consider pursuing another deal of that size, Friel said, "In most cases when we look at larger transactions the risk aspects of the deal can sometimes outweigh the potential benefits," Friel said.

"Something like that of that size would have to be a transaction that we felt really created significant value for our shareholders, that was something that was just so attractive that we felt we really needed to take a look at it," he added.

PerkinElmer, which sells scientific instruments, medical testing equipment and environmental safety monitoring products, has historically made several acquisitions each year in the $50 million to $100 million range.

Friel said the company was eyeing somewhat larger deals.

"Our preference would be to start doing a little bigger than that. We got a couple in the pipeline that look pretty interesting that would be more in the couple hundred million range," he said.

"We generate a lot of cash so we have fairly significant borrowing capacity, so we feel good about our financial position from the perspective of going out and doing these $100 to $200 million acquisitions to add to the capabilities of what we have. And I think that's what you'll see from us going forward," Friel said.

His preference would be acquisitions in the areas of diagnostics, reagents and services and software, and deals that would expand the company's geographic reach.

"The core strategy of the company is fundamentally based on smaller type bolt-on acquisitions," he said.

(Reporting by Bill Berkrot; Editing by Richard Chang)